Search
Type
Audience
Category
Issue
Last updated
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 15 of 414 items.
UPDATE: June 29, 2022
There continues to be a national shortage of specialized infant formulas for infants with food allergies and certain medical conditions. This includes extensively hydrolyzed formulas and amino acid-based formulas. There is no…
AlertPublic advisory | 2022-06-29
UPDATE (June 15, 2022):
Health Canada is warning consumers about additional unauthorized products seized from three herbal medicine stores in Calgary, Alberta, after testing found they contain drugs that are not listed on the product label, which may…
AlertPublic advisory | 2022-06-16
Health Canada is advising Canadians about unauthorized health products that may pose serious health risks. The table is updated when Health Canada finds unauthorized health products that are promoted for sexual enhancement, weight loss, as a workout aid…
AlertPublic advisory | 2022-06-16
A new presentation of SPIKEVAX (elasomeran) with a concentration of 0.10 mg/mL in a 2.5 mL multidose vial was authorized on June 01, 2022. In order to provide rapid access to the new presentation of SPIKEVAX (0.10 mg/mL, 2.5 mL multidose vial), Moderna…
AlertHealth professional risk communication | 2022-06-06
Health Canada is advising Canadians about unauthorized health products that may pose serious health risks. The table is updated when Health Canada finds unauthorized health products that are promoted for sexual enhancement, weight loss, as a workout aid…
AlertPublic advisory | 2022-06-03
Health Canada is warning Canadians of the serious danger posed by DigitDots magnet sets that were sold to Canadians online by HD Premier.
These sets contain small, powerful magnets that can be easily swallowed by children of all ages, posing serious…
AlertPublic advisory | 2022-05-12
August 25, 2019
For immediate release
OTTAWA – Health Canada is reminding Canadians that plasma pens are not authorized for sale in Canada and that these devices may pose health risks. Health Canada is also underlining that consumers should be wary…
AlertInformation update | 2022-05-11
November 26, 2018
For immediate release
OTTAWA – Health Canada is advising consumers that plasma pens (also known as “fibroblast” devices) promoted for cosmetic skin treatments such as eyelid lifts, wrinkle reduction and…
AlertInformation update | 2022-05-11
UPDATED INFORMATION – June 10, 2022
Further to the communication below, issued on May 9, 2022, Health Canada has issued a new DIN (i.e. DIN 02527863) for COMIRNATY (COVID-19 Vaccine, mRNA), 30 mcg/0.3 mL, which has a GRAY vial cap and GRAY label…
AlertHealth professional risk communication | 2022-05-09
Teva Canada Ltd. is recalling one lot each of Pharmasave Advanced Relief Eye Drops and Compliments Advanced Relief Eye Drops because of a packaging error. Some bottles may contain ingredients that are not listed on the label and that may pose health…
AlertPublic advisory | 2022-05-07
Apotex Inc. is recalling certain lots of Apo-Acyclovir (acyclovir) tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity (N-nitrosodimethylamine [NDMA]) above the acceptable level.
Apo-Acyclovir is a…
AlertPublic advisory | 2022-04-28
UPDATE: April 21, 2022 – Pfizer recalls Accupril blood pressure tablets due to a nitrosamine impurity
Pfizer Canada ULC is recalling all lots of the prescription drug Accupril (quinapril hydrochloride) in 10 mg, 20 mg and 40 mg strengths due to the…
AlertPublic advisory | 2022-04-21
Certain lots of hand sanitizers do not meet Health Canada requirements. Issues include:
containing (or possibly containing) ingredients that are not permitted by Health Canada;
containing undeclared impurities at elevated levels;
improper…
AlertPublic advisory | 2022-04-20
Sotrovimab, 500 mg IV, is unlikely to maintain efficacy against the Omicron BA.2 subvariant. Sotrovimab demonstrates reduced in vitro neutralization against the Omicron BA.2 subvariant.
Audience
Healthcare professionals responsible…
AlertHealth professional risk communication | 2022-04-14
EVUSHELD (tixagevimab and cilgavimab for injection) was authorized by Health Canada on April 14, 2022. In order to provide rapid access to EVUSHELD in the context of the global COVID-19 pandemic, AstraZeneca will distribute product vials and cartons with…
AlertHealth professional risk communication | 2022-04-14